DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

• Published in: Molecular cancer Vol. 20; no. 1; p. 134
• Main Authors: Kizhakeyil, Atish, Zaini, Nurmahirah Binte Mohammed, Poh, Zhi Sheng, Wong, Brandon Han Siang, Loh, Xinpeng, Ng, Aik Seng, Low, Zun Siong, Prasannan, Praseetha, Gong, Chun, Tan, Michelle Guet Khim, Nagarajan, Chandramouli, Huang, Dachuan, Lu, Pang Wan, Lim, Jing Quan, Barrans, Sharon, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Follows, George, Hodson, Daniel J, Du, Ming Qing, Goh, Yeow Tee, Tan, Suat Hoon, Grigoropoulos, Nicholas Francis, Verma, Navin Kumar
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.10.2021; BioMed Central; BMC
• Subjects: Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; B-cell lymphoma; Biomarkers, Tumor; Burkitt's lymphoma; Cancer; Care and treatment; Cell adhesion; Cell Line, Tumor; Chemoresistance; Cyclin D1 - genetics; DDX3X mutation; DEAD-box RNA Helicases - deficiency; Disease Progression; DNA helicase; Drug resistance; Drug Resistance, Neoplasm - genetics; Gene regulation; Genomes; Hematolymphoid malignancy; Hodgkin's lymphoma; Humans; Letter to the Editor; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - diagnosis; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - genetics; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Non-Hodgkin - diagnosis; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - genetics; Lymphoma, Non-Hodgkin - metabolism; MAP kinase; Medical prognosis; Mitogen-Activated Protein Kinases - metabolism; Mutation; Non-Hodgkin's lymphomas; Phosphorylation; Prognosis; RNA helicase; Signal transduction; Stat3 protein; STAT3 Transcription Factor - metabolism; T cells; Transcription; Tumour metastasis; Whole Exome Sequencing; DDX3X mutation; Hematolymphoid malignancy; Prognosis; Tumour metastasis; Drug resistance
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-021-01437-0

Keywords: DDX3X mutation, Hematolymphoid malignancy, Prognosis, Tumour metastasis, Drug resistance